NLS Pharmaceutics (NCEL) Income Statement (2018 - 2025)
Annual Income Statement report data from Dec 31, 2018 to Dec 31, 2025 for NLS Pharmaceutics (NCEL).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
Operating Expenses | ||||||||
Research And Development | 1.13M (+14.14%) | 990K (-38.51%) | 1.61M (-82.07%) | 8.98M (+51.69%) | 5.92M (+5820.00%) | 100K (-88.89%) | 900K (+26.76%) | 710K |
Selling General And Administrative | 1.35M (+66.67%) | 810K (-39.10%) | 1.33M (-79.57%) | 6.51M (+9.60%) | 5.94M (+170.00%) | 2.20M (-33.33%) | 3.30M (+20.44%) | 2.74M |
Operating Expenses | 2.47M (-43.61%) | 4.38M (-62.91%) | 12M (-23.71%) | 15M (+30.52%) | 12M (+415.65%) | 2.30M (-45.24%) | 4.20M (+21.74%) | 3.45M |
Depreciation And Amortization | 60K (-85.37%) | 410K (-33.87%) | 620K (+6100.00%) | 10K (0.00%) | 10K | - | - | - |
Operating Income | ||||||||
Operating Income | -2.56M (+23.67%) | -2.07M (-31.23%) | -3.01M (-80.56%) | -15.48M (+30.52%) | -11.86M (+415.65%) | -2.30M (-45.24%) | -4.20M (+21.74%) | -3.45M |
Ebit | -2.56M (+23.67%) | -2.07M (-31.23%) | -3.01M (-80.56%) | -15.48M (+30.52%) | -11.86M (+415.65%) | -2.30M (-45.24%) | -4.20M (+21.74%) | -3.45M |
EBITDA | -2.51M (+52.12%) | -1.65M (-30.96%) | -2.39M (-84.55%) | -15.47M (+30.55%) | -11.85M (+327.80%) | -2.77M (-49.17%) | -5.45M (+5.83%) | -5.15M |
Other Income / Expenses | ||||||||
Interest Expense | - | 50K (-58.33%) | 120K (+20.00%) | 100K (+100.00%) | 50K (-44.44%) | 90K | - | - |
Net Interest Income | - | - | -120.00K (+20.00%) | -100.00K (+100.00%) | -50.00K | - | - | - |
Other Non Operating Income | -100.00K (+11.11%) | -90.00K (-18.18%) | -110.00K | 10K | -20.00K (-93.94%) | -330.00K (+371.43%) | -70.00K | 20K |
Net Income | ||||||||
Income Before Tax | - | -7.20M (+119.51%) | -3.28M | - | - | - | - | - |
Net Income From Continuing Operations | -8.30M (+15.28%) | -7.20M (+116.22%) | -3.33M (-79.82%) | -16.50M (+38.08%) | -11.95M (+317.83%) | -2.86M (-47.52%) | -5.45M (+5.83%) | -5.15M |
Net Income | -8.30M (+15.28%) | -7.20M (+116.22%) | -3.33M (-79.82%) | -16.50M (+38.08%) | -11.95M (+317.83%) | -2.86M (-47.52%) | -5.45M (+5.83%) | -5.15M |
Comprehensive Income Net Of Tax | -9.05M (+24.14%) | -7.29M (+112.54%) | -3.43M (-79.07%) | -16.39M (+35.68%) | -12.08M (+322.38%) | -2.86M (-47.52%) | -5.45M (+5.83%) | -5.15M |